Skip to main content
40°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arvinas Inc.
< Previous
1
2
Next >
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
February 20, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
February 06, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
February 01, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Appoints Jared Freedberg as General Counsel
January 16, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas Announces Oversubscribed $350 Million Private Placement
November 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas Announces Changes to its Board of Directors
June 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
June 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
PFE
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Present at Stifel Targeted Oncology Day
April 21, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
April 03, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
February 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 23, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Participate in Upcoming Investor Conferences
February 06, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
Arvinas Announces Changes to its Board of Directors
December 16, 2022
From
Arvinas Inc.
Via
GlobeNewswire
Tickers
ARVN
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
